Artemisia Annua

1. What conditions has Artemisia annua been studied for?

• Malaria (and other parasitic protozoan infections): Artemisinin (from Artemisia annua) and derivatives are established antimalarials; a review also summarizes activity against multiple non-malarial protozoa (e.g., Leishmania, Trypanosoma, Toxoplasma, Giardia, Cryptosporidium, Babesia) in vitro and in vivo.

• Cancer:

  • General anticancer potential of artemisinin derivatives (ARTs) discussed in a review (mechanisms and early clinical studies).

  • Colorectal cancer: dihydroartemisinin (DHA) studied with a targeted nano-delivery system to improve bioavailability and antitumor effects (in vitro and in vivo).

  • Hypoxic tumors: terpenoids from A. annua evaluated as inhibitors of carbonic anhydrase IX (CAIX), an enzyme overexpressed in hypoxic tumor environments (in vitro + in silico).

• Inflammation / neuroinflammation models: ethanolic extracts (especially 90% ethanol leaf extract) and artemisinin showed protective effects against LPS-induced inflammatory stimulus in SH-SY5Y neuroblastoma cells, including reduced TNF-α mRNA.

• Autoimmune diseases: a review summarizes “accumulating evidence” for immunoregulatory properties and potential therapeutic viability of artemisinin and derivatives across major autoimmune diseases (mechanistic and translational focus).

• Respiratory diseases: a review summarizes artesunate’s proven/potential effects in asthma, COPD, lung injury, lung cancer, pulmonary fibrosis, and COVID-19 across in silico, in vitro, in vivo studies (including clinical trials).

• Antibacterial/antibiotic-resistant infections (plant extract research): abstracts indicate investigation of leaf/stem ethanolic extracts for inhibitory potential against bacteria (details truncated in provided text).

• Animal production/health (geese): dietary supplementation (1% A. annua) studied for growth performance, antioxidant capacity, immunity, intestinal morphology, and gut microbiota.

• Food preservation/material applications: essential oil used as a UV absorber in chitosan/pullulan films to preserve grape berries (not a human health condition, but a studied application).

• Related constituent research (chlorogenic acid, CGA): CGA (formed from caffeic acid + quinic acid; present in A. annua among other plants) studied for kidney fibrosis in a mouse UUO model and HK-2 cell fibrosis model via TLR4/NF-κB modulation. (This is evidence for a constituent associated with A. annua, not necessarily for whole-plant supplementation.)

2. Does it work in treating those conditions? Summarize the evidence.

• Malaria: The abstracts state artemisinin and semi-synthetic derivatives are “well-known and efficacious antimalarial drugs,” indicating strong clinical effectiveness (standard-of-care class). The provided text does not include trial details, but the claim reflects established clinical use.

• Other protozoan infections: A review concludes artemisinin/derivatives show activity against many protozoa in vitro and in vivo and “may be good alternatives,” but emphasizes that more studies are needed before clinical application. Overall: promising preclinical evidence; insufficient clinical confirmation in the abstract.

• Cancer (artemisinin derivatives broadly): A review summarizes preclinical mechanisms (notably reactive oxygen species production and cell-cycle effects) and mentions clinical studies focused mainly on efficacy/safety/dose-ranging. Overall: substantial preclinical rationale; clinical evidence appears early/limited based on the abstract.

• Colorectal cancer (DHA nano-delivery): The nano-system improved DHA bioavailability and showed “outstanding therapeutic effectiveness both in vitro and in vivo,” with proposed mechanisms including ROS-induced ferroptosis/apoptosis and immunogenic cell death. However, this is not evidence that oral A. annua supplements treat colorectal cancer; it is a drug-delivery research platform and remains preclinical in the abstract.

• Hypoxic tumors (CAIX inhibition): Terpenoids isolated from A. annua were tested against CAIX using in vitro assays and computational methods; manool was the most potent inhibitor among those tested (IC value truncated). This supports a biochemical anticancer target interaction, but not clinical efficacy.

• Inflammatory stimulus in neuronal cells: Ethanolic extracts (especially 90% ethanol leaf extract) and artemisinin reduced LPS-related inflammatory signaling in SH-SY5Y cells, including reduced TNF-α mRNA. This supports anti-inflammatory potential in a cell model; it does not establish clinical benefit for human inflammatory diseases.

• Autoimmune diseases: The review describes “promising therapeutic potential” and summarizes immunoregulatory properties and mechanisms. Based on the abstract alone, this is supportive but not definitive; it does not provide specific clinical outcomes.

• Respiratory diseases (artesunate): The review concludes artesunate is “promising” across multiple respiratory disorders via anti-inflammatory/anti-oxidative and other mechanisms, drawing on in silico/in vitro/in vivo studies and including clinical trials. The abstract does not quantify clinical efficacy; overall evidence appears mixed and indication-dependent, with stronger mechanistic/preclinical support than definitive clinical proof (from the abstract alone).

• Geese (feed additive): In a controlled 21-day feeding experiment, 1% dietary A. annua improved growth metrics (BW, ADG, ADFI; reduced FCR), increased antioxidant enzymes (CAT, GSH-Px, SOD, T-AOC), lowered MDA, increased several immune markers (IgA/IgG/IgM, lysozyme), reduced IFN-γ and IL-6, improved jejunal morphology, and shifted cecal microbiota (increased diversity; higher relative abundance of Bacteroides, Fecalibacterium, Paraprevotella). This is positive evidence in an animal agriculture context, not direct evidence for human clinical outcomes.

• Kidney fibrosis (CGA constituent): In mice with UUO, CGA (40–80 mg/kg/day for 10 days) alleviated injury, inflammation, oxidative stress, and fibrosis; in HK-2 cells it inhibited inflammatory/oxidative processes, with multi-omics and docking pointing to TLR4/NF-κB regulation. This supports CGA as an antifibrotic candidate, but it is not direct evidence that A. annua supplementation treats kidney fibrosis in humans.

3. What health benefits does it have?

• Proven antimalarial benefit (drug class): Artemisinin and derivatives are described as efficacious antimalarial drugs (clear established benefit, though this refers to pharmaceutical preparations rather than typical dietary supplements).

• Anti-inflammatory potential: In an LPS-stimulated cell model, A. annua ethanolic extracts and artemisinin showed protective effects; the 90% ethanol leaf extract reduced TNF-α mRNA under LPS stimulation.

• Antioxidant and immune-support signals (animal data): In geese, 1% dietary A. annua increased antioxidant enzyme activities (CAT, GSH-Px, SOD), increased total antioxidant capacity, reduced lipid peroxidation marker MDA, and increased immunoglobulins and lysozyme at various time points.

• Gut and intestinal effects (animal data): In geese, improved jejunal morphology (reduced crypt depth; increased villus height/crypt depth) and increased cecal microbiota diversity with shifts toward taxa often associated with fiber fermentation and gut health (e.g., Fecalibacterium).

• Anticancer/adjunct potential (preclinical + early clinical signals): Reviews and preclinical studies suggest artemisinin derivatives can induce oxidative stress in cancer cells and affect cell cycle; targeted delivery systems for DHA show strong in vitro/in vivo antitumor effects. These are promising but not definitive for routine clinical use as supplements.

• Potential immunoregulatory effects: A review highlights artemisinins’ immunoregulatory properties relevant to autoimmune diseases, suggesting possible benefit pending stronger clinical validation.

4. Does it have any downsides or side effects?

The provided abstracts contain limited direct safety/adverse-effect reporting for Artemisia annua as a supplement. Key limitations and plausible downsides based on what is (and is not) in the abstracts:

• Evidence gap for supplement safety: Several abstracts are reviews or preclinical studies (cell/animal), which do not establish human safety profiles for whole-plant products or long-term use.

• Drug-like activity implies drug-like risks: Artemisinin derivatives are potent pharmaceuticals. Reviews mention clinical studies focusing on “safety and dose-ranging” in oncology contexts, implying that tolerability and dosing constraints exist, but the abstract does not specify adverse events.

• Immunomodulation could be double-edged: The autoimmune-disease review emphasizes immunoregulatory effects. In principle, immune modulation can carry risks (e.g., infection susceptibility or immune imbalance), but the abstract does not provide specific harms.

• Formulation/bioavailability challenges: DHA’s “low water solubility and bioavailability” is explicitly noted, which is a practical downside for achieving consistent exposure with simple formulations (and a reason advanced delivery systems are being developed).

• Animal study did not highlight harms at tested dose: In the geese study, 1% dietary inclusion improved multiple outcomes over 21 days; the abstract does not report adverse effects. This does not guarantee safety in humans or at different doses/durations.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (e.g., genotype-stratified efficacy, toxicity, or dosing) for Artemisia annua, artemisinin, artesunate, or related constituents.

• No direct evidence in these abstracts: None mention specific genetic variants (e.g., CYP polymorphisms, transporter genes, immune-response variants) affecting response or risk.

• Important limitation: Because artemisinin derivatives are drug-like and used clinically, pharmacogenomic factors could be relevant in principle, but conclusions cannot be drawn from the supplied abstracts.

References

1. Pharmacological insights into the multifaceted biological properties of quinic acid.
   Taoufiq Benali, Saad Bakrim, Rokaia Ghchime, Nisrine Benkhaira, Nasreddine El Omari, Abdelaali Balahbib, Doaue Taha, Gökhan Zengin, Mohammad Mehedi Hasan, Shabana Bibi, Abdelhakim Bouyahya (2024) - Biotechnology & genetic engineering reviews
2. How Can Synergism of Traditional Medicines Benefit from Network Pharmacology?
   Haidan Yuan, Qianqian Ma, Heying Cui, Guancheng Liu, Xiaoyan Zhao (2017)
3. Dynamic interactions and inhibitory mechanisms of Artemisia annua terpenoids with carbonic anhydrase IX.
   Emadeldin M Kamel, Faris F Aba Alkhayl, Haifa A Alqhtani, May Bin-Jumah, Al Mokhtar Lamsabhi (2024) - International journal of biological macromolecules
4. Antibacterial and Phytochemical Screening of Artemisia Species.
   Maria-Evelina Bordean, Rodica Ana Ungur, Dan Alexandru Toc, Ileana Monica Borda, Georgiana Smaranda Marțiș, Carmen Rodica Pop, Miuța Filip, Mihaela Vlassa, Bogdana Adriana Nasui, Anamaria Pop, Delia Cinteză, Florina Ligia Popa, Sabina Marian, Lidia Gizella Szanto, Sevastița Muste (2023) - Antioxidants (Basel, Switzerland)
5. Chitosan-pullulan films enriched with Artemisia annua essential oil: Characterization and application in grape preservation.
   Wendan Chen, Hua Liu, Yuhong Chai, Chenghu Guo, Chang Luo, Dongliang Chen, Xi Cheng, Fengjun Wang, Conglin Huang (2023) - International journal of biological macromolecules
6. Effects of dietary Artemisia annua supplementation on growth performance, antioxidant capacity, immune function, and gut microbiota of geese.
   Yizhe Cui, Xinyang Leng, Yujie Zhao, Yu Zhao, Qiuju Wang (2024) - Poultry science
7. Anticancer Activity of Artemisinin and its Derivatives.
   Silvia Slezakova, Jana Ruda-Kucerova (2017) - Anticancer research
8. Artemisia annua L. polysaccharide improves the growth performance and intestinal barrier function of broilers challenged with Escherichia coli.
   Shiwei Guo, Binlin Shi, Yuanyuan Xing, Yuanqing Xu, Xiao Jin, Lei Hong, Shengnan Zhang, Min Qiao, Sumei Yan (2024) - Frontiers in microbiology
9. Artemisinins: Promising drug candidates for the treatment of autoimmune diseases.
   Xu Gao, Xian Lin, Qingwen Wang, Jian Chen (2024) - Medicinal research reviews
10. Secondary Metabolites Isolated from
    Lahngong Methodius Shinyuy, Gisèle E Loe, Olivia Jansen, Lúcia Mamede, Allison Ledoux, Sandra Fankem Noukimi, Suh Nchang Abenwie, Stephen Mbigha Ghogomu, Jacob Souopgui, Annie Robert, Kristiaan Demeyer, Michel Frederich (2023) - Metabolites
11. Phytochemical Analysis and Anti-Inflammatory Activity of Different Ethanolic Phyto-Extracts ofArtemisia annuaL
    Giulia Abate, Leilei Zhang, Mariachiara Pucci, Giulia Morbini, Eileen Mac Sweeney (2021)
12. A pH and glutathione-responsive carbon monoxide-driven nano-herb delivery system for enhanced immunotherapy in colorectal cancer.
    Chen Yang, Hui Ming, Bowen Li, Shanshan Liu, Lihua Chen, Tingting Zhang, Yajie Gao, Tao He, Canhua Huang, Zhongyan Du (2024) - Journal of controlled release : official journal of the Controlled Release Society
13. Chlorogenic acid alleviate kidney fibrosis through regulating TLR4/NF-қB mediated oxidative stress and inflammation.
    Hao Jiao, Meijuan Zhang, Wuqin Xu, Tongshuai Pan, Jiajie Luan, Yingjie Zhao, Zhirui Zhang (2024) - Journal of ethnopharmacology
14. Artemisinin and its derivatives in treating protozoan infections beyond malaria.
    Cecilia Shi Ni Loo, Nelson Siu Kei Lam, Deying Yu, Xin-Zhuan Su, Fangli Lu (2017) - Pharmacological research
15. Artesunate: A review of its therapeutic insights in respiratory diseases.
    Jingyuan Zhang, Yun Li, Jingxuan Wan, Mengyuan Zhang, Chunxiao Li, Jiangtao Lin (2022) - Phytomedicine : international journal of phytotherapy and phytopharmacology
16. Artemisinin-type drugs for the treatment of hematological malignancies.
    R I Mancuso, M A Foglio, S T Olalla Saad (2021) - Cancer chemotherapy and pharmacology
17. Extraction, Isolation and Characterization of Bioactive Compounds from
    Rosemary Anibogwu, Karl De Jesus, Samjhana Pradhan, Srinath Pashikanti, Sameena Mateen, Kavita Sharma (2021) - Molecules (Basel, Switzerland)
18. Antiviral, virucidal and antioxidant properties of Artemisia annua against SARS-CoV-2.
    Melissa Baggieri, Silvia Gioacchini, Gigliola Borgonovo, Giorgia Catinella, Antonella Marchi, Pasquale Picone, Sonya Vasto, Raoul Fioravanti, Paola Bucci, Maedeh Kojouri, Roberto Giuseppetti, Emilio D'Ugo, Fausto Ubaldi, Sabrina Dallavalle, Domenico Nuzzo, Andrea Pinto, Fabio Magurano (2023) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
19. In vitro and in vivo anti-eczema effect of Artemisia annua aqueous extract and its component profiling.
    Yifan Zhao, Le Zhu, Lan Yang, Mo Chen, Peng Sun, Yue Ma, Dong Zhang, Ya Zhao, Haidong Jia (2024) - Journal of ethnopharmacology
20. Artemisia annua Extract Attenuate Doxorubicin-Induced Hepatic Injury via PI-3K/Akt/Nrf-2-Mediated Signaling Pathway in Rats.
    Karim Samy El-Said, Ahmed S Haidyrah, Maysa A Mobasher, Arwa Ishaq A Khayyat, Afnan Shakoori, Noorah Saleh Al-Sowayan, Ibrahim Omar Barnawi, Reham A Mariah (2023) - International journal of molecular sciences